Soleus Capital Master Fund, L.P. 13D and 13G filings for Pieris Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-02 09:59 am Sale |
2023-12-31 | 13G | Pieris Pharmaceuticals, Inc. PIRS |
Soleus Capital Master Fund, L.P. | 0 0.000% |
-50,000 (Position Closed) |
Filing |
| 2023-01-27 5:02 pm Purchase |
2023-01-25 | 13G | Pieris Pharmaceuticals, Inc. PIRS |
Soleus Capital Master Fund, L.P. | 50,000 5.400% |
37,500 (+300.00%) |
Filing |
| 2023-01-26 5:01 pm Sale |
2022-12-31 | 13G | Pieris Pharmaceuticals, Inc. PIRS |
Soleus Capital Master Fund, L.P. | 12,500 1.300% |
-36,061 (-74.26%) |
Filing |
| 2022-01-27 4:30 pm Purchase |
2022-01-24 | 13G | Pieris Pharmaceuticals, Inc. PIRS |
Soleus Capital Master Fund, L.P. | 48,561 5.400% |
48,561 (New Position) |
Filing |